DGCR2 Antibody

What is DGCR2 and why is it important in biomedical research?

DGCR2 (DiGeorge Syndrome Critical Region Gene 2) is a membrane protein with significant roles in multiple biological systems. In humans, the canonical protein consists of 550 amino acid residues with a molecular mass of approximately 61 kDa . DGCR2 has emerged as a critical research target for two main reasons:

• It shows beta-cell specificity in pancreatic tissue, making it valuable for diabetes research and targeted drug delivery

• It's associated with neurodevelopmental processes, with implications in DiGeorge syndrome and schizophrenia vulnerability through its role in cortical formation

The protein contains both a C-type lectin domain and a cysteine-rich region similar to that found in low-density lipoprotein receptors . It functions as an adhesion receptor protein potentially involved in neural crest cell migration, a process altered in DiGeorge syndrome .

How do I select the appropriate DGCR2 antibody for my specific application?

Selection should be based on several experimental parameters:

For immunohistochemistry applications, data suggests optimal results when using TE buffer pH 9.0 for antigen retrieval, though citrate buffer pH 6.0 serves as an acceptable alternative for certain tissue types . When selecting an antibody, consider:

• Target epitope location (N-terminal, C-terminal, or internal regions)

• Sample type (human, mouse, rat tissue compatibility)

• Detection method requirements

• Validation data available for your specific application

What are the established protocols for DGCR2 immunodetection in tissue samples?

For effective immunohistochemical detection of DGCR2 in tissue sections:

• Fix tissues in 4% paraformaldehyde (20 minutes at room temperature)

• Prepare frozen cryosections (optimal thickness: 10 μm)

• Block with 3% donkey serum in PBS (30 minutes)

• Apply primary antibodies:

  • Anti-DGCR2 polyclonal rabbit antibody (1:400 dilution)

  • For co-localization studies: include antibodies against relevant markers (e.g., insulin at 1:400 for beta cell studies)

• Incubate overnight at 4°C

• Apply appropriate secondary antibodies (1:300 dilution):

  • Alexa Fluor 488-conjugated donkey anti-rabbit for DGCR2

  • Specific secondary antibodies for co-staining markers

• Counterstain nuclei with DAPI

• Visualize using confocal microscopy

This protocol has been validated for both stem cell-derived islets and primary human islets, demonstrating robust and specific labeling of DGCR2-expressing cells .

How is DGCR2 being utilized for targeted beta cell imaging and drug delivery?

DGCR2 has emerged as a promising target for diabetes research due to its specificity to pancreatic beta cells. Recent advances include:

The development of Affibody molecules (small affinity proteins) that specifically target human DGCR2 with nanomolar affinity. The lead candidate, ZDGCR2:AM106, demonstrated:

• Excellent thermal stability and biodistribution properties

• Negligible toxicity to islets

• Suitable pharmacokinetic profile for imaging applications

• Potential as a delivery vehicle for therapeutic agents

This approach addresses a significant challenge in diabetes research: the need for systems that can increase drug exposure specifically in pancreatic beta cells while minimizing off-target effects and toxicity. The methodology employs directed evolution techniques to generate high-affinity binders that can be conjugated to imaging reagents or therapeutic compounds .

What experimental approaches can validate DGCR2 expression in pancreatic beta cells?

Multiple complementary techniques should be employed:

• Immunofluorescence co-localization:

  • Double-staining with anti-DGCR2 and anti-insulin antibodies

  • Confocal microscopy to confirm cellular co-localization

  • Analysis in both primary human islets and stem cell-derived beta cells

• Western blot analysis:

  • Protein extraction from isolated islets or beta cell lines

  • Probing with anti-DGCR2 antibodies (expected band: 45-65 kDa)

  • Comparison with positive control tissues (brain, heart)

• Flow cytometry:

  • Dispersed islet cells labeled with fluorescent-conjugated DGCR2 antibodies

  • Analysis of co-expression with established beta cell markers

• Functional validation:

  • Binding assays using recombinant DGCR2 protein

  • Surface plasmon resonance (SPR) with immobilized DGCR2 to confirm specific binding

  • Multiple concentration analyses (1-100 nM) performed in triplicates

What are the technical challenges in developing DGCR2-targeted molecular imaging agents?

Developing effective DGCR2-targeted imaging requires addressing several technical challenges:

• Affinity and specificity optimization:

  • Directed evolution methods are required to generate binding molecules with sufficiently high affinity (nanomolar range)

  • Surface plasmon resonance validation using varying concentrations (1-100 nM) to establish binding kinetics

• In vivo biodistribution concerns:

  • Targeting agents must demonstrate appropriate biodistribution for pancreatic imaging

  • Rapid blood clearance is desirable for imaging contrast

  • Targeting molecules must efficiently extravasate from blood vessels and penetrate pancreatic tissue

• Conjugation chemistry considerations:

  • Site-specific conjugation techniques (such as maleimide chemistry with C-terminal cysteine residues) are necessary to preserve binding activity

  • The conjugated imaging moiety must not interfere with target binding

• Toxicity evaluation:

  • Comprehensive toxicity assessment for both the targeting molecule and any conjugated imaging agents

  • Particular attention to preserving beta cell viability and function

How does DGCR2 function in neurodevelopment and what are the implications for DiGeorge syndrome?

DGCR2 plays critical roles in neurodevelopmental processes:

• Cortical formation mechanisms:

  • DGCR2 regulates early corticogenesis, potentially through Reelin-dependent pathways

  • Deletion of DGCR2 demonstrates measurable impact on cortical formation

  • These disruptions may contribute to neurodevelopmental aspects of 22q11.2 deletion syndrome

• Neural crest cell migration:

  • DGCR2 functions as an adhesion receptor protein

  • It may regulate migration of neural crest cells during development

  • Disruption of this process is hypothesized to contribute to DiGeorge syndrome phenotypes

• Schizophrenia vulnerability:

  • DGCR2 has been implicated in vulnerability to schizophrenia

  • This connection provides insight into the elevated schizophrenia risk observed in patients with 22q11.2 deletion syndrome

The implications for DiGeorge syndrome research are substantial, as DGCR2 deletion represents one of multiple genes in the 22q11.2 region whose deletion contributes to the variable phenotype ranging from mild symptoms to severe intellectual disability, facial dysmorphism, heart defects, and urogenital abnormalities .

What methodological approaches are most effective for studying DGCR2 expression patterns in neural tissues?

For comprehensive analysis of DGCR2 in neural tissues:

• Immunohistochemical analysis:

  • Protocol optimization: Use TE buffer pH 9.0 for antigen retrieval in brain tissue

  • Dilution series testing: Start with 1:50-1:500 dilutions for IHC applications

  • Positive control: Use confirmed human brain tissue samples

• Developmental expression profiling:

  • Time-course analysis across developmental stages

  • Region-specific examination of expression patterns

  • Co-localization with neural developmental markers

• Single-cell RNA sequencing:

  • Cell type-specific expression analysis

  • Developmental trajectory mapping

  • Identification of co-expressed gene networks

• In situ hybridization complementation:

  • Validate protein expression findings with mRNA localization

  • Use RNAscope or similar technologies for sensitive detection

  • Perform dual ISH/IHC for comprehensive analysis

How can researchers effectively detect DGCR2 protein variants in neuropsychiatric disease models?

Effective detection strategies for DGCR2 variants include:

• Western blot optimization for variant detection:

  • Adjust gel percentage based on expected molecular weight differences

  • Use reducing conditions for optimal detection (as validated for DGCR2)

  • Protein from Hep3B human hepatocellular carcinoma, Hepa 1-6 mouse hepatoma, and H4-II-E-C3 rat hepatoma cell lines serve as positive controls

  • Expected band size: approximately 45 kDa under reducing conditions

• Comparative antibody selection:

  • Test multiple antibodies targeting different epitopes

  • Validate specificity in knockout/knockdown systems

  • Positive controls should include tissues with known high expression (brain, heart, lung)

• Mass spectrometry-based approaches:

  • Targeted proteomics for specific variant detection

  • Post-translational modification analysis (particularly glycosylation, which has been reported for DGCR2)

  • Integration with genomic data for variant correlation

• Functional characterization:

  • Cell adhesion assays to assess variant impact on function

  • Subcellular localization studies to detect trafficking differences

  • Interaction proteomics to identify altered binding partners

What approaches can address non-specific binding when using DGCR2 antibodies in complex tissue samples?

When encountering non-specific binding:

• Optimization of blocking conditions:

  • Extend blocking time (up to 2 hours) with 3-5% serum from the same species as the secondary antibody

  • Consider adding 0.1-0.3% Triton X-100 to blocking solution for improved penetration

  • Test alternative blocking agents (BSA, milk proteins, commercial blockers)

• Antibody dilution optimization:

  • Perform careful titration experiments (starting range: 1:50-1:500 for IHC)

  • Extend primary antibody incubation time at more dilute concentrations

  • Consider signal amplification systems for higher dilutions

• Sample preparation refinements:

  • Optimize fixation protocols (duration, fixative composition)

  • Compare antigen retrieval methods (TE buffer pH 9.0 shows superior results for DGCR2 compared to citrate buffer pH 6.0)

  • Include absorption controls with recombinant DGCR2 protein

• Advanced detection systems:

  • Tyramide signal amplification for enhanced specificity

  • Fluorophore selection to minimize tissue autofluorescence

  • Consider multispectral imaging to distinguish true signal

How can researchers differentiate between DGCR2 isoforms in experimental systems?

For precise DGCR2 isoform differentiation:

• Isoform-specific antibody selection:

  • Use antibodies targeting unique epitopes in specific isoforms

  • Validate with recombinant protein standards of each isoform

  • Consider generating custom antibodies against isoform-specific sequences

• RT-PCR strategies:

  • Design primer sets spanning isoform-specific exon junctions

  • Perform quantitative real-time PCR for relative isoform abundance

  • Validate with sequencing of amplified products

• Advanced protein separation techniques:

  • 2D gel electrophoresis to separate isoforms based on both size and charge

  • Isoelectric focusing combined with western blotting

  • High-resolution SDS-PAGE systems with extended separation ranges

• Recombinant expression systems:

  • Generate isoform-specific standards for comparison

  • Express in relevant cell systems to assess functional differences

  • Use as positive controls for antibody validation

What are the most effective strategies for DGCR2 protein purification for antibody validation?

For optimal DGCR2 purification:

• Expression system selection:

  • For full-length membrane protein: Mammalian expression systems

  • For soluble domains: Bacterial systems with appropriate chaperones

  • Insect cell systems for glycosylated versions

• Purification approaches:

  • Affinity chromatography using cobalt resin for His-tagged recombinant DGCR2

  • Size exclusion chromatography for higher purity

  • Consider detergent solubilization strategies for membrane-bound portions

• Quality control measures:

  • SDS-PAGE for purity assessment

  • Mass spectrometry for identity confirmation

  • Circular dichroism for folding verification

  • Surface plasmon resonance for functional validation

• Storage considerations:

  • Aliquot and store at -20°C

  • Add stabilizing agents (glycerol at 50% final concentration)

  • Avoid repeated freeze-thaw cycles to maintain functionality

How do DGCR2-targeting affibody molecules compare with traditional antibodies for beta cell imaging?

Affibody molecules targeting DGCR2 (particularly ZDGCR2:AM106) demonstrated favorable pharmacokinetic profiles with rapid extravasation from blood and efficient tissue penetration. This makes them particularly suitable for molecular imaging applications where high contrast and rapid clearance of unbound tracer are desirable . These properties are directly connected to their small size, which enables rapid renal clearance.

Traditional antibodies offer advantages in terms of established detection systems and widespread availability of secondary reagents but may be limited by their larger size for certain in vivo applications .

What emerging applications exist for DGCR2 in cancer research?

Recent findings reveal potential applications in cancer research:

• Prognostic biomarker development:

  • DGCR2 expression, together with USP18, has emerged as a potential prognostic marker for muscle-invasive bladder cancer patient survival

  • Expression pattern analysis may provide insights into disease progression and treatment response

• Hepatocellular carcinoma research:

  • DGCR2 expression has been detected in multiple hepatoma cell lines (Hep3B human, Hepa 1-6 mouse, H4-II-E-C3 rat)

  • This suggests potential roles in liver cancer biology requiring further investigation

• Targeted therapy approaches:

  • The established affibody targeting platform could potentially be adapted for cancer-specific applications

  • Conjugation with cytotoxic agents could enable targeted cancer therapies if cancer-specific expression patterns are identified

• Diagnostic imaging development:

  • If differential expression in cancerous tissues is confirmed, DGCR2-targeted imaging could provide novel diagnostic approaches

  • The established molecular imaging techniques from diabetes research could be translated to oncology applications

How can researchers integrate computational approaches with experimental DGCR2 antibody validation?

Integrating computational and experimental approaches:

• Epitope prediction and antibody design:

  • In silico analysis of DGCR2 protein structure to identify optimal epitopes

  • Antigenicity and accessibility prediction algorithms to guide antibody selection

  • Molecular docking simulations to predict binding interactions

• Cross-reactivity assessment:

  • Sequence homology analysis across species to predict cross-reactivity

  • DGCR2 shows 93% amino acid sequence identity between human and mouse and 92% between human and rat in the mature extracellular domain

  • Protein structure prediction to identify conserved binding regions

• Validation data integration:

  • Machine learning approaches to analyze antibody validation datasets

  • Pattern recognition in immunohistochemical staining results

  • Integration of data from different validation methods (WB, IHC, ELISA)

• Systems biology perspective:

  • Network analysis of DGCR2 interactions and signaling pathways

  • Integration with transcriptomic and proteomic datasets

  • Contextual analysis of expression patterns across tissues and disease states

How should researchers interpret contradictory findings when studying DGCR2 expression across different tissues?

When facing contradictory expression data:

• Methodological differences analysis:

  • Compare antibody epitopes (N-terminal, C-terminal, internal regions)

  • Evaluate fixation and tissue processing protocols

  • Assess detection system sensitivities and thresholds

• Tissue-specific regulation considerations:

  • DGCR2 demonstrates differential expression across tissue types, with notable presence in:

    • Brain, heart, and lung (high expression)

    • Pancreatic beta cells (specific expression)

    • Fetal kidney (developmental expression)

  • Consider developmental stage and physiological context of samples

• Isoform-specific expression patterns:

  • Determine if contradictions relate to specific isoform detection

  • Up to three different isoforms have been reported for DGCR2

  • Design experiments to specifically differentiate between isoforms

• Validation through orthogonal methods:

  • Complement protein detection with mRNA analysis

  • Use multiple antibodies targeting different epitopes

  • Consider functional assays to confirm biological relevance

What controls are essential when validating a novel DGCR2 antibody for research applications?

A comprehensive validation approach requires:

• Positive control tissues/cells:

  • Brain tissue (known high expression)

  • Heart and lung tissue (reported expression)

  • Hepatoma cell lines (Hep3B, Hepa 1-6, H4-II-E-C3)

  • Pancreatic beta cells and stem cell-derived islets

• Negative controls:

  • Genetic knockdown/knockout systems where available

  • Secondary antibody-only controls

  • Isotype-matched irrelevant antibody controls

  • Peptide competition/absorption controls

• Cross-reactivity assessment:

  • Testing across intended species (human, mouse, rat)

  • Evaluation in tissues known to lack expression

  • Western blot molecular weight verification (expected 61-65 kDa)

• Application-specific validation:

  • For Western blot: Reducing vs. non-reducing conditions comparison

  • For IHC: Antigen retrieval method optimization

  • For ELISA: Standard curve generation with recombinant protein

  • All applications: Concentration/dilution optimization

What are the ethical and methodological considerations for translating DGCR2-based research into clinical applications?

Critical considerations include:

• Translational research ethics:

  • Patient consent for tissue usage in DGCR2 expression studies

  • Careful evaluation of risks for in vivo imaging approaches

  • Consideration of genetic testing implications in DiGeorge syndrome research

• Methodological validation requirements:

  • Rigorous reproducibility testing across multiple laboratories

  • Standardization of protocols for clinical application

  • Development of reference standards for quantitative measurements

• Safety considerations for targeting agents:

  • Toxicology evaluations beyond initial cell culture studies

  • Immunogenicity assessments for repeated administrations

  • Pharmacokinetic and biodistribution studies in appropriate models

• Regulatory pathway planning:

  • DGCR2 antibodies and targeting agents are currently designated "For Research Use Only"

  • Development of GMP-compliant production methods for clinical translation

  • Design of validation studies meeting regulatory requirements for intended use